Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Melanoma

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 145 articles:
HTML format



Single Articles


    March 2021
  1. HARBOUR JW
    Therapeutic Escape in Galphaq-Mutant Uveal Melanoma: It's a FAK.
    Clin Cancer Res. 2021 Mar 25. pii: 1078-0432.CCR-21-0567.
    PubMed     Abstract available


  2. NAJJAR YG, McCurry D, Lin H, Lin Y, et al
    Neoadjuvant Pembrolizumab and High Dose Interferon Alfa-2b in Resectable Regionally Advanced Melanoma.
    Clin Cancer Res. 2021 Mar 22. pii: 1078-0432.CCR-20-4301.
    PubMed     Abstract available


    February 2021
  3. NGUYEN TT, Ramsay L, Ahanfeshar-Adams M, Lajoie M, et al
    Mutations in the IFNgamma-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment.
    Clin Cancer Res. 2021 Feb 16. pii: 1078-0432.CCR-20-3365.
    PubMed     Abstract available


  4. KELLY G, Al-Ejeh F, McCuaig RD, Casciello F, et al
    G9a inhibition enhances checkpoint inhibitor blockade response in melanoma.
    Clin Cancer Res. 2021 Feb 15. pii: 1078-0432.CCR-20-3463.
    PubMed     Abstract available


  5. PARADIS JS, Acosta M, Saddawi-Konefka R, Kishore A, et al
    Synthetic Lethal Screens Reveal Co-Targeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma.
    Clin Cancer Res. 2021 Feb 10. pii: 1078-0432.CCR-20-3363.
    PubMed     Abstract available


    January 2021
  6. SHOUSHTARI AN, Chatila WK, Arora A, Sanchez-Vega F, et al
    Therapeutic Implications of Detecting MAP Kinase Activating Alterations in Cutaneous and Unknown Primary Melanomas.
    Clin Cancer Res. 2021 Jan 28. pii: 1078-0432.CCR-20-4189.
    PubMed     Abstract available


  7. MARTINEZ-MORILLA S, Villarroel-Espindola F, Wong PF, Toki MI, et al
    Biomarker Discovery in Immunotherapy-treated Melanoma Patients with Imaging Mass Cytometry.
    Clin Cancer Res. 2021 Jan 27. pii: 1078-0432.CCR-20-3340.
    PubMed     Abstract available


  8. GEIGER T, Beck L, Harel M, Yu S, et al
    Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ-Specificity and Treatment Resistance.
    Clin Cancer Res. 2021 Jan 14. pii: 1078-0432.CCR-20-3752.
    PubMed     Abstract available


  9. ATKINS MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, et al
    The State of Melanoma: Emergent Challenges and Opportunities.
    Clin Cancer Res. 2021 Jan 7. pii: 1078-0432.CCR-20-4092.
    PubMed     Abstract available


    December 2020
  10. NEELATURE SRIRAMAREDDY S, Smalley KSM
    MEK-ing the most of it: strategies to co-target Galphaq and MAPK in uveal melanoma.
    Clin Cancer Res. 2020 Dec 22. pii: 1078-0432.CCR-20-4530.
    PubMed     Abstract available


  11. MAKOHON-MOORE AP, Lipson EJ, Hooper JE, Zucker A, et al
    The genetic evolution of treatment-resistant cutaneous, acral and uveal melanomas.
    Clin Cancer Res. 2020 Dec 15. pii: 1078-0432.CCR-20-2984.
    PubMed     Abstract available


  12. MONTFORT A, Filleron T, Virazels M, Dufau C, et al
    Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase 1b clinical trial.
    Clin Cancer Res. 2020 Dec 3. pii: 1078-0432.CCR-20-3449.
    PubMed     Abstract available


    November 2020
  13. HITCHMAN TD, Bayshtok G, Ceraudo E, Moore AR, et al
    Combined Inhibition of Galphaq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma.
    Clin Cancer Res. 2020 Nov 23. pii: 1078-0432.CCR-20-2860.
    PubMed     Abstract available


  14. JOHANNET P, Coudray N, Donnelly DM, Jour G, et al
    Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma.
    Clin Cancer Res. 2020 Nov 18. pii: 1078-0432.CCR-20-2415.
    PubMed     Abstract available


  15. MUELLER KL, Theoret MR, Lemery SJ, Amiri-Kordestani L, et al
    Neoadjuvant Therapy for Melanoma: A US Food and Drug Administration - Melanoma Research Alliance Public Workshop.
    Clin Cancer Res. 2020 Nov 13. pii: 1078-0432.CCR-20-3285.
    PubMed     Abstract available


  16. SALAMA AKS, Palta M, Rushing CN, Selim MA, et al
    Ipilimumab and Radiation in Patients with High Risk Resected or Regionally Advanced Melanoma.
    Clin Cancer Res. 2020 Nov 10. pii: 1078-0432.CCR-20-2452.
    PubMed     Abstract available


    October 2020
  17. GANDHI S, Pandey MR, Attwood K, Ji W, et al
    Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
    Clin Cancer Res. 2020 Oct 30. pii: 1078-0432.CCR-20-2381.
    PubMed     Abstract available


  18. FANE ME, Ecker BL, Kaur A, Marino GE, et al
    sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.
    Clin Cancer Res. 2020 Oct 23. pii: 1078-0432.CCR-20-0446.
    PubMed     Abstract available


  19. MARSAVELA G, Lee J, Calapre L, Wong SQ, et al
    Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy.
    Clin Cancer Res. 2020 Oct 16. pii: 1078-0432.CCR-20-2251.
    PubMed     Abstract available


  20. CHUA V, Mattei J, Han A, Johnston L, et al
    The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019).
    Clin Cancer Res. 2020 Oct 15. pii: 1078-0432.CCR-20-2536.
    PubMed     Abstract available


    September 2020
  21. TANG B, Chi Z, Chen Y, Liu X, et al
    Correction: Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial.
    Clin Cancer Res. 2020;26:5048.
    PubMed    


  22. TRUONG A, Yoo JH, Scherzer M, Sanchez JMS, et al
    Chloroquine sensitizes GNAQ/11-mutated melanoma to MEK1/2 inhibition.
    Clin Cancer Res. 2020 Sep 15. pii: 1078-0432.CCR-20-1675.
    PubMed     Abstract available


    August 2020
  23. MARUSAK C, Thakur V, Li Y, Freitas JT, et al
    Targeting Extracellular Matrix Remodeling restores BRAF Inhibitor Sensitivity in BRAFi Resistant Melanoma.
    Clin Cancer Res. 2020 Aug 20. pii: 1078-0432.CCR-19-2773.
    PubMed     Abstract available


  24. MIDDLETON MR, McAlpine C, Woodcock VK, Corrie P, et al
    Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated anti-tumor immune responses in patients with metastatic melanoma.
    Clin Cancer Res. 2020 Aug 18. pii: 1078-0432.CCR-20-1247.
    PubMed     Abstract available


    June 2020
  25. CARLINO MS, Menzies AM, Atkinson VG, Cebon JS, et al
    Long-Term Follow-Up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients With Advanced Melanoma: KEYNOTE-029 Part 1B.
    Clin Cancer Res. 2020 Jun 30. pii: 1078-0432.CCR-20-0177.
    PubMed     Abstract available


  26. CHAUVIN JM, Ka M, Pagliano O, Menna C, et al
    IL-15 stimulation with TIGIT blockade reverses CD155-mediated NK cell dysfunction in melanoma.
    Clin Cancer Res. 2020 Jun 26. pii: 1078-0432.CCR-20-0575.
    PubMed     Abstract available


  27. SHOUSHTARI AN, Bao R, Luke JJ
    PD-1 Blockade in Chinese versus Western Patients with Melanoma.
    Clin Cancer Res. 2020 Jun 2. pii: 1078-0432.CCR-20-1558.
    PubMed     Abstract available


    May 2020
  28. HAMID O, Bruno R, Fasso M, O'Hear C, et al
    Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Response.
    Clin Cancer Res. 2020;26:2436.
    PubMed    


  29. GOLDSTEIN DA, Ratain MJ
    Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Letter.
    Clin Cancer Res. 2020;26:2435.
    PubMed    


  30. PATEL SP, Othus M, Chae YK, Kurzrock R, et al
    Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response.
    Clin Cancer Res. 2020;26:2434.
    PubMed    


  31. SONBOL MB, Halfdanarson TR
    Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter.
    Clin Cancer Res. 2020;26:2433.
    PubMed    


  32. ALGAZI AP, Twitty CG, Tsai KK, Le M, et al
    Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma.
    Clin Cancer Res. 2020 May 6. pii: 1078-0432.CCR-19-2217.
    PubMed     Abstract available


  33. GLITZA OLIVA IC, Tawbi HA
    "Liquid Gold" - The unTAPped Potential of Cerebrospinal Fluid Analysis?
    Clin Cancer Res. 2020;26:2083-2084.
    PubMed     Abstract available


  34. WEBER JS, Postow MA
    TNFalpha Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?
    Clin Cancer Res. 2020;26:2085-2086.
    PubMed     Abstract available


    April 2020
  35. LEPLETIER A, Madore J, O'Donnell JS, Johnston RL, et al
    Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma.
    Clin Cancer Res. 2020 Apr 28. pii: 1078-0432.CCR-19-3925.
    PubMed     Abstract available


  36. LEE JH, Menzies AM, Carlino MS, McEvoy AC, et al
    Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors.
    Clin Cancer Res. 2020 Apr 22. pii: 1078-0432.CCR-19-3926.
    PubMed     Abstract available


  37. TANG B, Chi Z, Chen YB, Liu X, et al
    Safety, Efficacy and Biomarker Analysis of Toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial.
    Clin Cancer Res. 2020 Apr 22. pii: 1078-0432.CCR-19-3922.
    PubMed     Abstract available


  38. BASLER L, Gabrys HS, Hogan SA, Pavic M, et al
    Radiomics, tumor volume and blood biomarkers for early prediction of pseudoprogression in metastatic melanoma patients treated with immune checkpoint inhibition.
    Clin Cancer Res. 2020 Apr 6. pii: 1078-0432.CCR-20-0020.
    PubMed     Abstract available


  39. ICHIKAWA J, Yoshida T, Isser A, Laino AS, et al
    Rapid Expansion of Highly Functional Antigen-Specific T cells from Melanoma Patients by Nanoscale Artificial Antigen Presenting Cells.
    Clin Cancer Res. 2020 Apr 2. pii: 1078-0432.CCR-19-3487.
    PubMed     Abstract available


    March 2020
  40. SHATTUCK-BRANDT RL, Chen SC, Murray E, Johnson CA, et al
    Metastatic Melanoma Patient-derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
    Clin Cancer Res. 2020 Mar 31. pii: 1078-0432.CCR-19-1895.
    PubMed     Abstract available


  41. POSTOW MA, Knox SJ, Goldman DA, Elhanati Y, et al
    A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.
    Clin Cancer Res. 2020 Mar 23. pii: 1078-0432.CCR-19-3936.
    PubMed     Abstract available


  42. CHUNG JS, Ramani V, Kobayashi M, Fattah F, et al
    DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors.
    Clin Cancer Res. 2020;26:1449-1459.
    PubMed     Abstract available


  43. YANG RK, Kuznetsov IB, Ranheim EA, Wei JS, et al
    Outcome-related signatures identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated After Starting Hu14.18-IL2.
    Clin Cancer Res. 2020 Mar 9. pii: 1078-0432.CCR-19-3294.
    PubMed     Abstract available


    February 2020
  44. WATANABE T, Gaedicke S, Guffart E, Firat E, et al
    Adding Indoximod to Hypofractionated Radiotherapy with Anti-PD-1 Checkpoint Blockade Enhances Early NK and CD8(+) T-Cell-Dependent Tumor Activity.
    Clin Cancer Res. 2020;26:945-956.
    PubMed     Abstract available


  45. LI C, Guo W, Ma J, Yang Y, et al
    ATP-citrate lyase epigenetically potentiates oxidative phosphorylation to promote melanoma growth and adaptive resistance to MAPK inhibition.
    Clin Cancer Res. 2020 Feb 7. pii: 1078-0432.CCR-19-1359.
    PubMed     Abstract available


  46. LUCCI A, Hall C, Patel SP, Narendran B, et al
    Circulating tumor cells and early relapse in node-positive melanoma.
    Clin Cancer Res. 2020 Feb 3. pii: 1078-0432.CCR-19-2670.
    PubMed     Abstract available


    January 2020
  47. VERHEIJDEN RJ, May AM, Blank CU, Aarts MJB, et al
    Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1 treated patients in the Dutch Melanoma Treatment Registry.
    Clin Cancer Res. 2020 Jan 27. pii: 1078-0432.CCR-19-3322.
    PubMed     Abstract available


  48. SMALLEY I, Law V, Wyatt C, Evernden B, et al
    Proteomic analysis of CSF from patients with leptomeningeal melanoma metastases identifies signatures associated with disease progression and therapeutic resistance.
    Clin Cancer Res. 2020 Jan 10. pii: 1078-0432.CCR-19-2840.
    PubMed     Abstract available


    November 2019
  49. RIBAS A, Daud A, Pavlick AC, Gonzalez R, et al
    Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.
    Clin Cancer Res. 2019 Nov 15. pii: 1078-0432.CCR-18-4180.
    PubMed     Abstract available


  50. DIZIER B, Callegaro A, Debois M, Dreno B, et al
    A T-helper 1/interferon- gene signature is prognostic in the adjuvant setting of resectable high-risk melanoma but not in non-small cell lung cancer.
    Clin Cancer Res. 2019 Nov 15. pii: 1078-0432.CCR-18-3717.
    PubMed     Abstract available


    October 2019
  51. KULKARNI PM, Robinson EJ, Sarin Pradhan J, Gartrell-Corrado RD, et al
    Deep learning based on standard H&E images of primary melanoma tumors identifies patients at risk for visceral recurrence and death.
    Clin Cancer Res. 2019 Oct 21. pii: 1078-0432.CCR-19-1495.
    PubMed     Abstract available


    September 2019
  52. NAMIKAWA K, Aung PP, Milton DR, Tetzlaff MT, et al
    Correlation of tumor burden in sentinel lymph nodes with tumor burden in non-sentinel lymph nodes and survival in cutaneous melanoma.
    Clin Cancer Res. 2019 Sep 30. pii: 1078-0432.CCR-19-1194.
    PubMed     Abstract available


  53. LUKE JJ, Olson DJ, Allred JB, Strand CA, et al
    Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201).
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-19-1223.
    PubMed     Abstract available


  54. DI GIACOMO AM, Covre A, Finotello F, Rieder D, et al
    Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial.
    Clin Cancer Res. 2019 Sep 17. pii: 1078-0432.CCR-19-1335.
    PubMed     Abstract available


  55. THAKUR R, Laye JP, Lauss M, Diaz JMS, et al
    Transcriptomic analysis reveals prognostic molecular signatures of stage I melanoma.
    Clin Cancer Res. 2019 Sep 12. pii: 1078-0432.CCR-18-3659.
    PubMed     Abstract available


  56. EDWARDS J, Batten M, Ferguson A, Palendira U, et al
    Novel Immune Targets in Melanoma-Response.
    Clin Cancer Res. 2019;25:5424-5425.
    PubMed    


  57. NOCENTINI G, Cari L, Riccardi C
    Novel Immune Targets in Melanoma-Letter.
    Clin Cancer Res. 2019;25:5422-5423.
    PubMed    


    August 2019
  58. JIANG H, Shin DH, Nguyen TT, Fueyo J, et al
    Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.
    Clin Cancer Res. 2019 Aug 27. pii: 1078-0432.CCR-19-0405.
    PubMed     Abstract available


  59. VASHISHT GOPAL YN, Gammon ST, Prasad R, Knighton B, et al
    A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor-resistance in melanoma.
    Clin Cancer Res. 2019 Aug 22. pii: 1078-0432.CCR-19-0836.
    PubMed     Abstract available


  60. ALOIA A, Mullhaupt D, Chabbert CD, Eberhart T, et al
    A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors.
    Clin Cancer Res. 2019 Aug 2. pii: 1078-0432.CCR-19-0253.
    PubMed     Abstract available


  61. KONG Y, Yu J, Yan J, Guo Q, et al
    Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma.
    Clin Cancer Res. 2019 Aug 2. pii: 1078-0432.CCR-19-0475.
    PubMed     Abstract available


  62. PENG W, Williams LJ, Xu C, Melendez B, et al
    Anti-OX40 antibody directly enhances the function of tumor-reactive CD8(+) T cells and synergizes with PI3Kbeta inhibition in PTEN loss melanoma.
    Clin Cancer Res. 2019 Aug 1. pii: 1078-0432.CCR-19-1259.
    PubMed     Abstract available


    July 2019
  63. HAMID O, Molinero L, Bolen CR, Sosman JA, et al
    Safety, Clinical Activity, and Biological Correlates of Response in Patients With Metastatic Melanoma: Results From a Phase I trial of Atezolizumab.
    Clin Cancer Res. 2019 Jul 29. pii: 1078-0432.CCR-18-3488.
    PubMed     Abstract available


  64. FIELD MG, Kuznetsov JN, Bussies PL, Cai L, et al
    BAP1 loss is associated with DNA methylomic repatterning in highly aggressive Class 2 uveal melanomas.
    Clin Cancer Res. 2019 Jul 8. pii: 1078-0432.CCR-19-0366.
    PubMed     Abstract available


    June 2019
  65. FAIAO-FLORES F, Emmons MF, Durante MA, Kinose F, et al
    HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma.
    Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-18-3382.
    PubMed     Abstract available


  66. ANBUNATHAN H, Verstraten R, Singh AD, Harbour JW, et al
    Integrative copy number analysis of uveal melanoma reveals novel candidate genes involved in tumorigenesis including a tumor suppressor role for PHF10/BAF45a.
    Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-18-3052.
    PubMed     Abstract available


  67. RODRIGUES M, Mobuchon L, Houy A, Alsafadi S, et al
    Evolutionary routes in metastatic uveal melanomas depend on MBD4 alterations.
    Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-19-1215.
    PubMed     Abstract available


  68. TOKI MI, Merritt CR, Wong PF, Smithy JW, et al
    High-plex predictive marker discovery for melanoma immunotherapy treated patients using Digital Spatial Profiling.
    Clin Cancer Res. 2019 Jun 12. pii: 1078-0432.CCR-19-0104.
    PubMed     Abstract available


    May 2019
  69. LUKE JJ, Bao R, Sweis RF, Spranger S, et al
    WNT/beta-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
    Clin Cancer Res. 2019;25:3074-3083.
    PubMed     Abstract available


  70. GOFF SL, Rosenberg SA
    BRAF Inhibition: Bridge or Boost to T-cell Therapy?
    Clin Cancer Res. 2019;25:2682-2684.
    PubMed     Abstract available


    April 2019
  71. COHEN JV, Sullivan RJ
    Developments in the space of new MAPK pathway inhibitors for BRAF-mutant melanoma.
    Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-18-0836.
    PubMed     Abstract available


  72. SHOUSHTARI AN
    About Face: Molecular Aberrations in Head and Neck Mucosal Melanomas.
    Clin Cancer Res. 2019 Apr 5. pii: 1078-0432.CCR-19-0658.
    PubMed     Abstract available


  73. WU RY, Kong PF, Xia L, Huang Y, et al
    Regorafenib promotes anti-tumor immunity via inhibiting PD-L1 and IDO1 expression in melanoma.
    Clin Cancer Res. 2019 Apr 2. pii: 1078-0432.CCR-18-2840.
    PubMed     Abstract available


    March 2019
  74. WEISS SA, Wolchok JD, Sznol M
    Immunotherapy of melanoma: facts and hopes.
    Clin Cancer Res. 2019 Mar 28. pii: 1078-0432.CCR-18-1550.
    PubMed     Abstract available


  75. YAN Y, Wongchenko MJ, Robert C, Larkin J, et al
    Genomic features of exceptional response in vemurafenib +/- cobimetinib-treated patients with BRAFV600-mutated metastatic melanoma.
    Clin Cancer Res. 2019 Mar 1. pii: 1078-0432.CCR-18-0720.
    PubMed     Abstract available


  76. JOHNSON DB, Balko JM
    Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?
    Clin Cancer Res. 2019;25:1452-1454.
    PubMed     Abstract available


    February 2019
  77. ZHOU R, Shi C, Tao W, Li J, et al
    Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations.
    Clin Cancer Res. 2019 Feb 19. pii: 1078-0432.CCR-18-3442.
    PubMed     Abstract available


  78. EDWARDS JJ, Tasker A, Silva I, Quek C, et al
    Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naive melanoma: implications for clinical trials.
    Clin Cancer Res. 2019 Feb 18. pii: 1078-0432.CCR-18-4011.
    PubMed     Abstract available


  79. ATAY C, Kwak T, Lavilla-Alonso S, Donthireddy L, et al
    BRAF targeting sensitizes resistant melanoma to cytotoxic T cells.
    Clin Cancer Res. 2019 Feb 14. pii: 1078-0432.CCR-18-2725.
    PubMed     Abstract available


    January 2019
  80. GARTRELL RD, Marks DK, Rizk EM, Bogardus M, et al
    Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.
    Clin Cancer Res. 2019 Jan 15. pii: 1078-0432.CCR-18-2847.
    PubMed     Abstract available


  81. PIRES DA SILVA I, Wang KYX, Wilmott JS, Holst J, et al
    Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.
    Clin Cancer Res. 2019 Jan 10. pii: 1078-0432.CCR-18-1680.
    PubMed     Abstract available


  82. WONG PF, Wei W, Smithy JW, Acs B, et al
    Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma.
    Clin Cancer Res. 2019 Jan 7. pii: 1078-0432.CCR-18-2652.
    PubMed     Abstract available


    December 2018
  83. VAN MEIR EG, Dong L, You S, Zhang Q, et al
    Arylsulfonamide 64B inhibits hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma.
    Clin Cancer Res. 2018 Dec 18. pii: 1078-0432.CCR-18-1368.
    PubMed     Abstract available


  84. KIM SH, Roszik J, Cho SN, Ogata D, et al
    The COX2 effector microsomal PGE2 synthase-1 is a regulator of immunosuppression in cutaneous melanoma.
    Clin Cancer Res. 2018 Dec 11. pii: 1078-0432.CCR-18-1163.
    PubMed     Abstract available


  85. JOSEPH RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, et al
    Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
    Clin Cancer Res. 2018;24:6098.
    PubMed    


    November 2018
  86. TARHINI AA, Lee SJ, Li X, Rao UN, et al
    E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High Dose Interferon-alpha2b in Advanced Melanoma.
    Clin Cancer Res. 2018 Nov 12. pii: 1078-0432.CCR-18-2258.
    PubMed     Abstract available


  87. LIM SY, Lee JH, Gide TN, Menzies AM, et al
    Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy.
    Clin Cancer Res. 2018 Nov 8. pii: 1078-0432.CCR-18-2795.
    PubMed     Abstract available


    August 2018
  88. WOODS D, Ramakrishnan R, Laino AS, Berglund AE, et al
    Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T-cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma.
    Clin Cancer Res. 2018 Aug 21. pii: 1078-0432.CCR-18-1100.
    PubMed     Abstract available


  89. GOTTESDIENER LS, O'Connor S, Busam KJ, Won H, et al
    Rates of ERBB2 Alterations Across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-amplified Acral Melanoma.
    Clin Cancer Res. 2018 Aug 9. pii: 1078-0432.CCR-18-1397.
    PubMed     Abstract available


    July 2018
  90. TOKER A, Nguyen LT, Stone SC, Yang C, et al
    Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma.
    Clin Cancer Res. 2018 Jul 31. pii: 1078-0432.CCR-18-0554.
    PubMed     Abstract available


  91. JOHNSON DB, Dahlman KB
    Class matters: Sensitivity of BRAF-mutant melanoma to MAPK inhibition.
    Clin Cancer Res. 2018 Jul 24. pii: 1078-0432.CCR-18-1795.
    PubMed     Abstract available


  92. JOHNSON DB, Bordeaux JM, Kim JY, Vaupel CA, et al
    Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma.
    Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-0309.
    PubMed     Abstract available


    June 2018
  93. PAWELEC G
    Unexpected benefits of aging for favorable responses to PD-1 blockade in melanoma?
    Clin Cancer Res. 2018 Jun 15. pii: 1078-0432.CCR-18-1475.
    PubMed     Abstract available


  94. DANKNER M, Lajoie M, Moldoveanu D, Nguyen TT, et al
    Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma.
    Clin Cancer Res. 2018 Jun 14. pii: 1078-0432.CCR-17-3384.
    PubMed     Abstract available


  95. WARNER AB, Postow MA
    Bigger is not always better: Tumor size and prognosis in advanced melanoma.
    Clin Cancer Res. 2018 Jun 14. pii: 1078-0432.CCR-18-1311.
    PubMed     Abstract available


    May 2018
  96. FORGET MA, Haymaker C, Hess KR, Meng YJ, et al
    Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome.
    Clin Cancer Res. 2018 May 30. pii: 1078-0432.CCR-17-3649.
    PubMed     Abstract available


  97. BEZROOKOVE V, Nosrati M, Miller JR, de Semir D, et al
    Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma.
    Clin Cancer Res. 2018 May 18. pii: 1078-0432.CCR-18-0791.
    PubMed     Abstract available


  98. TEH JLF, Aplin AE
    Playing the melanoma endgame.
    Clin Cancer Res. 2018 May 16. pii: 1078-0432.CCR-18-0989.
    PubMed     Abstract available


    April 2018
  99. JOSEPH RW, Elassaiss-Schaap J, Kefford RF, Hwu WJ, et al
    Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-2386.
    PubMed     Abstract available


  100. EROGLU Z, Chen YA, Gibney GT, Weber JS, et al
    Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma.
    Clin Cancer Res. 2018 Apr 19. pii: 1078-0432.CCR-18-0565.
    PubMed     Abstract available


  101. SANLORENZO M, Vujic I, Floris A, Novelli M, et al
    BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody.
    Clin Cancer Res. 2018 Apr 12. pii: 1078-0432.CCR-17-1914.
    PubMed     Abstract available


  102. YANG J, Hamid O, Carvajal RD
    The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma.
    Clin Cancer Res. 2018 Apr 2. pii: 1078-0432.CCR-18-0020.
    PubMed     Abstract available


    March 2018
  103. EDWARDS J, Wilmott JS, Madore J, Gide TN, et al
    CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy naive melanoma patients and expand significantly during anti-PD1 treatment.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-2257.
    PubMed     Abstract available


  104. ZHANG G, Wu LW, Mender I, Barzily-Rokni M, et al
    Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.
    Clin Cancer Res. 2018 Mar 21. pii: 1078-0432.CCR-17-2773.
    PubMed     Abstract available


  105. OO ZY, Stevenson AJ, Proctor MA, Daignault SM, et al
    Endogenous replication stress marks melanomas sensitive to CHK1 inhibitors in vivo.
    Clin Cancer Res. 2018 Mar 13. pii: 1078-0432.CCR-17-2701.
    PubMed     Abstract available


    January 2018
  106. ATKINS MB, Hodi FS, Thompson JA, McDermott D, et al
    Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase 1b KEYNOTE-029 study.
    Clin Cancer Res. 2018 Jan 22. pii: 1078-0432.CCR-17-3436.
    PubMed     Abstract available


  107. MARSHALL JF
    Targeting CDH17 in Cancer: When Blocking the Ligand Beats Blocking the Receptor?
    Clin Cancer Res. 2018;24:253-255.
    PubMed     Abstract available


    December 2017
  108. JIN Y, Zhang P, Wang Y, Jin B, et al
    Neddylation blockade diminishes hepatic metastasis by dampening cancer stem-like cells and angiogenesis in uveal melanoma.
    Clin Cancer Res. 2017 Dec 12. pii: 1078-0432.CCR-17-1703.
    PubMed     Abstract available


    November 2017
  109. GIDE TN, Wilmott JS, Scolyer RA, Long GV, et al
    Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
    Clin Cancer Res. 2017 Nov 10. pii: clincanres.2267.2017.
    PubMed     Abstract available


    October 2017
  110. KOSTER BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, et al
    Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.
    Clin Cancer Res. 2017;23:5679-5686.
    PubMed     Abstract available


    September 2017
  111. BARTOLOME RA, Aizpurua C, Jaen M, Torres S, et al
    Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis.
    Clin Cancer Res. 2017 Sep 15. pii: clincanres.1444.2017.
    PubMed     Abstract available


    August 2017
  112. ENNEN M, Keime C, Gambi G, Kieny A, et al
    MITF-high and MITF-low cells and a novel subpopulation expressing genes of both cell states contribute to intra and inter-tumoral heterogeneity of primary melanoma.
    Clin Cancer Res. 2017 Aug 28. pii: clincanres.0010.2017.
    PubMed     Abstract available


  113. KONG Y, Sheng X, Wu X, Yan J, et al
    Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma indicate the potential for CDK4/6 Inhibitors in Targeted Therapy.
    Clin Cancer Res. 2017 Aug 22. pii: clincanres.0070.2017.
    PubMed     Abstract available


  114. KASHANI-SABET M, Nosrati M, Miller J, Sagebiel R, et al
    Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.1317.2017.
    PubMed     Abstract available


    July 2017
  115. NIESSNER H, Sinnberg T, Kosnopfel C, Smalley KSM, et al
    BRAF inhibitors amplify the pro-apoptotic activity of MEK inhibitors by inducing ER stress in NRAS-mutant melanoma.
    Clin Cancer Res. 2017 Jul 19. pii: clincanres.0098.2017.
    PubMed     Abstract available


  116. KAKAVAND H, Rawson RV, Pupo GM, Yang JYH, et al
    PD-L1 expression and immune escape in melanoma resistanceto MAPK inhibitors.
    Clin Cancer Res. 2017 Jul 19. pii: clincanres.1688.2016.
    PubMed     Abstract available


  117. BAI X, Kong Y, Chi Z, Sheng X, et al
    MAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients a retrospective study of 2793 cases.
    Clin Cancer Res. 2017 Jul 18. pii: clincanres.0980.2017.
    PubMed     Abstract available


    June 2017
  118. DELORD JP, Robert C, Nyakas M, McArthur GA, et al
    Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.2923.2016.
    PubMed     Abstract available


  119. NISHINO M, Giobbie-Hurder A, Manos MP, Bailey N, et al
    Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.
    Clin Cancer Res. 2017 Jun 7. doi: 10.1158/1078-0432.CCR-17-0114.
    PubMed     Abstract available


    May 2017
  120. KULKARNI A, Al-Hraishawi H, Simhadri S, Hirshfield KM, et al
    BRAF fusion as a novel mechanism of acquired resistance to vemurafenib in BRAF V600E mutant melanoma.
    Clin Cancer Res. 2017 May 24. pii: clincanres.0758.2016.
    PubMed     Abstract available


  121. BUTTERFIELD LH, Zhao F, Lee S, Tarhini AA, et al
    Immune correlates of GM-CSF and melanoma peptide vaccination in a randomized trial for the adjuvant therapy of resected high-risk melanoma (E4697).
    Clin Cancer Res. 2017 May 23. pii: clincanres.3016.2016.
    PubMed     Abstract available


  122. WONGCHENKO MJ, McArthur GA, Dreno B, Larkin J, et al
    Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups With Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib.
    Clin Cancer Res. 2017 May 23. pii: clincanres.0172.2017.
    PubMed     Abstract available


  123. VILAIN RE, Menzies AM, Wilmott JS, Kakavand H, et al
    Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma.
    Clin Cancer Res. 2017 May 16. pii: clincanres.0698.2016.
    PubMed     Abstract available


  124. PARKHURST M, Gros A, Pasetto A, Prickett T, et al
    Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
    Clin Cancer Res. 2017;23:2491-2505.
    PubMed     Abstract available


  125. INFANTE JR, Hollebecque A, Postel-Vinay S, Bauer TM, et al
    Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.
    Clin Cancer Res. 2017;23:2423-2432.
    PubMed     Abstract available


    April 2017
  126. FRIEDMAN AA, Xia Y, Trippa L, Le LP, et al
    Feasibility of ultra-high-throughput functional screening of melanoma biopsies for discovery of novel cancer drug combinations.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.3029.2016.
    PubMed     Abstract available


  127. SUNSHINE JC, Nguyen P, Kaunitz G, Cottrell T, et al
    PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.
    Clin Cancer Res. 2017 Apr 20. pii: clincanres.1821.2016.
    PubMed     Abstract available


  128. SEGAL NH, Logan TF, Hodi FS, McDermott D, et al
    Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
    Clin Cancer Res. 2017;23:1929-1936.
    PubMed     Abstract available


  129. IIDA Y, Ciechanover A, Marzese DM, Hata K, et al
    Epigenetic Regulation of KPC1 Ubiquitin Ligase Effects the NF-kappaB Pathway in Melanoma.
    Clin Cancer Res. 2017 Apr 7. pii: clincanres.0146.2017.
    PubMed     Abstract available


    March 2017

  130. Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
    Clin Cancer Res. 2017;23:1361.
    PubMed    


    February 2017
  131. CHUK MK, Chang JT, Theoret MR, Sampene E, et al
    FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.
    Clin Cancer Res. 2017 Feb 24. pii: clincanres.0663.2016.
    PubMed     Abstract available


  132. BEHERA R, Kaur A, Webster MR, Kim S, et al
    Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of Klotho.
    Clin Cancer Res. 2017 Feb 23. pii: clincanres.0201.2017.
    PubMed     Abstract available


  133. EXLEY MA, Friedlander P, Alatrakchi N, Vriend L, et al
    Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: a Phase 1 Clinical Trial.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.0600.2016.
    PubMed     Abstract available


  134. BARONE A, Hazarika M, Theoret MR, Mishra-Kalyani P, et al
    FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma.
    Clin Cancer Res. 2017 Feb 8. pii: clincanres.0664.2016.
    PubMed     Abstract available


    January 2017
  135. DENIGER DC, Kwong ML, Pasetto A, Dudley ME, et al
    A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.
    Clin Cancer Res. 2017;23:351-362.
    PubMed     Abstract available


  136. HAZARIKA M, Chuk MK, Theoret MR, Mushti S, et al
    U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.
    Clin Cancer Res. 2017 Jan 13. pii: clincanres.0712.2016.
    PubMed     Abstract available


  137. BEAVER JA, Theoret MR, Mushti S, He K, et al
    FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.0714.2016.
    PubMed     Abstract available


    November 2016
  138. GANNON P, Baumgaertner P, Huber A, Iancu EM, et al
    Rapid and continued T cell differentiation into long-term effector and memory stem cells in vaccinated melanoma patients.
    Clin Cancer Res. 2016 Nov 21. pii: clincanres.1708.2016.
    PubMed     Abstract available


  139. NAGARAJAN P, Curry JL, Ning J, Piao J, et al
    Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: A retrospective review of 100 cases.
    Clin Cancer Res. 2016 Nov 18. pii: clincanres.2126.2016.
    PubMed     Abstract available


  140. SANGIOLO D, Gammaitoni L, Giraudo L, Macagno M, et al
    Cytokine Induced Killer cells kill chemo-surviving melanoma cancer stem cells.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1524.2016.
    PubMed     Abstract available


  141. KHALIL DN, Postow MA, Ibrahim N, Ludwig DL, et al
    An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.
    Clin Cancer Res. 2016;22:5204-5210.
    PubMed     Abstract available


    August 2016
  142. WINKLER F, Osswald M, Blaes J, Liao Y, et al
    Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1327.2016.
    PubMed     Abstract available


    April 2016
  143. KREPLER C, Xiao M, Sproesser K, Brafford PA, et al
    Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
    Clin Cancer Res. 2016;22:1592-602.
    PubMed     Abstract available


    March 2016
  144. KOHLHAPP FJ, Kaufman HL
    Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Clin Cancer Res. 2016;22:1048-54.
    PubMed     Abstract available


    February 2016
  145. CHARYCH DH, Hoch U, Langowski JL, Lee SR, et al
    NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.
    Clin Cancer Res. 2016;22:680-90.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: